| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Salarius Pharmaceuticals Inc (NASDAQ: SLRX)
SLRX Technical Analysis
4
| As on 9th Jun 2023 SLRX SHARE Price closed @ 1.65 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.54 & Strong Buy for SHORT-TERM with Stoploss of 0.46 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SLRXSHARE Price
| Open | 1.84 | Change | Price | % |
| High | 1.86 | 1 Day | -0.18 | -9.84 |
| Low | 1.62 | 1 Week | 0.24 | 17.02 |
| Close | 1.65 | 1 Month | -0.03 | -1.79 |
| Volume | 94084 | 1 Year | 1.12 | 211.32 |
| 52 Week High 5.00 | 52 Week Low 0.16 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| SLRX Daily Charts |
SLRX Intraday Charts |
Whats New @ Bazaartrend |
SLRX Free Analysis |
|
|
SLRX Important Levels Intraday
| RESISTANCE | 2.11 |
| RESISTANCE | 1.96 |
| RESISTANCE | 1.87 |
| RESISTANCE | 1.78 |
| SUPPORT | 1.52 |
| SUPPORT | 1.43 |
| SUPPORT | 1.34 |
| SUPPORT | 1.19 |
SLRX Forecast April 2024
| 4th UP Forecast | 1.9 |
| 3rd UP Forecast | 1.82 |
| 2nd UP Forecast | 1.77 |
| 1st UP Forecast | 1.72 |
| 1st DOWN Forecast | 1.58 |
| 2nd DOWN Forecast | 1.53 |
| 3rd DOWN Forecast | 1.48 |
| 4th DOWN Forecast | 1.4 |
SLRX Weekly Forecast
| 4th UP Forecast | 1.78 |
| 3rd UP Forecast | 1.74 |
| 2nd UP Forecast | 1.71 |
| 1st UP Forecast | 1.69 |
| 1st DOWN Forecast | 1.61 |
| 2nd DOWN Forecast | 1.59 |
| 3rd DOWN Forecast | 1.56 |
| 4th DOWN Forecast | 1.52 |
SLRX Forecast2024
| 4th UP Forecast | 11.92 |
| 3rd UP Forecast | 8.63 |
| 2nd UP Forecast | 6.59 |
| 1st UP Forecast | 4.55 |
| 1st DOWN Forecast | -1.25 |
| 2nd DOWN Forecast | -3.29 |
| 3rd DOWN Forecast | -5.33 |
| 4th DOWN Forecast | -8.62 |
Salarius Pharmaceuticals Inc ( NASDAQ USA Symbol : SLRX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SLRX Business Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and potential biomarkers for Seclidemstat (SP-2577). Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas. Address: 2450 Holcombe Boulevard, Houston, TX, United States, 77021
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service